Patients who have 4 or more migraine days per month and have failed on prophylactic treatment experience reduced quality of life, work productivity, and social activity involvement.
Patients with 4 or more migraine days per month who have failed on prophylactic treatment have reduced quality of life, work productivity, and social activity involvement, according to results of the My Migraine Voice survey.
Migraine significantly affects the lives of patients in all age groups. Among patients under 50 years old, migraine ranks first in years lived with disability.
Although the impact that migraines have on patients has been described in multiple studies, including the American Migraine Prevalence and Prevention Study and the Chronic Migraine Epidemiology and Outcomes study, information regarding patients with high migraine burden, specifically those experiencing 4 or more monthly migraine days and prophylaxis failure, has been limited. The My Migraine Voice survey detailed this patient subgroup.
Approximately 90% of the patients in the survey had taken preventive medication, and more than 80% had experienced 1 or more case of treatment failure. Taking into consideration the entire survey population, investigators found that migraine affected 9.8 days per month on average. Forty-four percent of the patients had migraine that lasted 1 to 2 days or more, and 19% of the patients reported migraine lasting longer than 3 days.
Half of the patients felt that migraine limited their daily activities, with most of the limitations occurring in the headache phase. Headache was also the main symptom that patients reported, along with light and sound sensitivity. Pain associated with migraines scored 7.4 out of 10.0 on average, with 57% of patients categorizing their pain as severe (8.0-10.0).
Patients who had 2 or more treatment failures reported a greater negative impact on daily functions associated with migraines than did those in the overall survey population (88% vs 85%, respectively). These patients also reported more cases of being fearful of experiencing another episode of migraine (33% vs 27%, respectively). Reliance on family and friends for daily tasks was also reported in 64% of patients with 2 or more treatment failures compared with 61% in overall survey population).
In 70% of the patients, migraines reduced work productivity. Some of the most common issues included inability to concentrate at work, missed days of work, and lack of understanding of their condition from coworkers. Missed days at work comprised an average of 4.6 working days, with 60% of patients reporting 1 or more missed days in the past month because of migraines. Although 63% of the patients reported that their employers were aware of their condition, only 9% of them were given disability-related allowance for their migraines.
Results from the survey indicate that although the general population is beginning to recognize the degree of disability that patients with migraines experience, greater understanding is still needed.
Reference:
Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventative treatments have failed. J Headache Pain. 2018;19(1):115. doi: 10.1186/s10194-018-0946-z.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen